Squamous Cell Carcinoma Clinical Trials

People with Squamous Cell Carcinoma of the Head and Neck (SCCHN) are asked to participate in a research study being conducted by Montefiore Medical Center, investigating adoptive cell therapy (ACT) of autologous tumor infiltrating lymphocytes (TIL). Study Drug: LN-145 is cellular study drug that utilizes an autologous TIL manufacturing therapy, ...

This trial is an open-label, single arm phase II study assessing the tolerability and anti-tumour activity of afatinib when given in combination with a fixed dose of pembrolizumab in patients with squamous NSCLC, who progressed during or after first line platinum-based standard therapy and had no prior treatment with an ...

All enrolled patients will receive CDX-3379 and cetuximab. All patients in the study will be closely monitored to determine if there is a response to the treatment and for any side effects that may occur.

To assess the efficacy of MEDI4736 monotherapy in terms of ORR.

People with Head and Neck Squamous Cell Carcinoma (HNSCC) are asked to participate in a research study being conducted by Montefiore Medical Center.

The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators would like to determine the percentage of patients with squamous cell lung cancers who experience shrinkage of their tumors following treatment with this ...

Participants will be screened for eligibility within 30 days of the intended start of the study treatment. Procedures for research purposes done during screening include archival tumor tissue collection for pharmacodynamic and predictive biomarker research and optional HPV status (if not already known). Eligible participants will take BYL719, by mouth, ...

This is a two-part Phase 1, non-randomized, open-label study of MM-151 plus MM-121 in patients with advanced, heregulin-positive lung, head and neck, and colorectal cancers. In part 1 of the study cohorts of 3 or more patients will be treated at escalating doses of MM-151 in combination with MM-121 until ...

This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with advanced solid tumors.

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.